{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:49:05Z","timestamp":1785876545984,"version":"3.56.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum AB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"F Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000329","name":"Novo Nordisk Haemophilia Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008322","name":"CSL Behring LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals USA Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jtha.2026.06.041","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:29:29Z","timestamp":1784042969000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factor VIII exposure, bleeding outcomes, and inhibitor development in 80 previously untreated patients and minimally treated patients with severe hemophilia A on emicizumab prophylaxis: real-world data from the PedNet Registry"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3521-1863","authenticated-orcid":false,"given":"Marloes","family":"de Kovel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gili","family":"Kenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayashree","family":"Motwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine G.","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Blatn\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Castaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Carcao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Escuriola Ettingshausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"K\u00f6nigs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Male","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Olivieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Oudot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Pergantou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Ranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Zapotocka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathelijn","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.T.","family":"Alvar\u00e8z Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O Benitez","family":"Hidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Blatny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"B\u00fchrlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Castaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Chambost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Rosa","family":"Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Eckhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Escuriola","family":"Ettingshausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N Gretenkort","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Holzhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kartal-Kaess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Klamroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"K\u00f6nigs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Labarque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"L\u00e5ngstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ljung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Male","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T Stamm","family":"Mikkelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"Molinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Motwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"R d\u2019Oiron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Olivieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Oudot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Pergantou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Van Geet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Z\u00e1potock\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Levy-Mendelovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Kenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Carcao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2026.06.041_bib1","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/hae.14729","article-title":"Primary prophylaxis in children with severe haemophilia A and B-Implementation over the last 20 years as illustrated in real-world data in the PedNet cohorts","volume":"29","author":"Ljung","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.06.041_bib2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood.2019000658","article-title":"Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A","volume":"134","author":"van den Berg","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.06.041_bib3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa1208024","article-title":"Factor VIII products and inhibitor development in severe hemophilia A","volume":"368","author":"Gouw","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.06.041_bib4","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/hae.13762","article-title":"The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab","volume":"25","author":"Carcao","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.06.041_bib5","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1016\/j.jtha.2025.07.010","article-title":"Predictors of immune tolerance induction success in 231 children with severe hemophilia A with high-titer inhibitors - lessons learned from the PedNet prospective cohort study","volume":"23","author":"Carcao","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.06.041_bib6","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/hae.14381","article-title":"Immune tolerance induction in severe haemophilia A: a UKHCDO inhibitor and paediatric working party consensus update","volume":"27","author":"Hart","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.06.041_bib7","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/hae.12613","article-title":"How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access","volume":"21","author":"Nijdam","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.06.041_bib8","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/hae.15015","article-title":"Bleeding control improves after switching to emicizumab: real-world experience of 177 children in the PedNet registry","volume":"30","author":"van der Zwet","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.06.041_bib9","first-page":"1329","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"142","author":"Callaghan","year":"2023","journal-title":"Erratum in: Blood"},{"key":"10.1016\/j.jtha.2026.06.041_bib10","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.06.041_bib11","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1182\/blood.2023021832","article-title":"Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial","volume":"143","author":"Pipe","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.06.041_bib12","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1182\/blood.2021011849","article-title":"Incidence and mortality rates of intracranial hemorrhage in hemophilia: a systematic review and meta-analysis","volume":"138","author":"Zwagemaker","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.06.041_bib13","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/hae.13848","article-title":"A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors","volume":"25","author":"Shima","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.06.041_bib14","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/bjh.16964","article-title":"Emicizumab treatment and monitoring in a paediatric cohort: real-world data","volume":"191","author":"Barg","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.06.041_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30941","article-title":"Single centre experience of the use of emicizumab in previously untreated and minimally treated patients under 18 months of age","volume":"71","author":"Hassan","year":"2024","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtha.2026.06.041_bib16","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/bjh.19312","article-title":"Emicizumab prophylaxis in infants: single-centre experience","volume":"204","author":"Levy-Mendelovich","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.06.041_bib17","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/hae.14847","article-title":"Dilemmas on emicizumab in children with haemophilia A: a survey of strategies from PedNet centres","volume":"29","author":"Ranta","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.06.041_bib18","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1111\/hae.12448","article-title":"Prospective observational cohort studies for studying rare diseases: the European PedNet Haemophilia Registry","volume":"20","author":"Fischer","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.06.041_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2025.109307","article-title":"A survey on clinical practice in monitoring and management of bleeding in children with haemophilia A on emicizumab prophylaxis in the PedNet centres","volume":"249","author":"Ranta","year":"2025","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.06.041_bib20","first-page":"1293","article-title":"Factor VIII genotype and the risk of developing high-responding or low-responding inhibitors in severe hemophilia A: data from the PedNet Hemophilia Cohort of 1,202 children","volume":"109","author":"Andersson","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2026.06.041_bib21","article-title":"Benchmarking prophylaxis with factor concentrates: reference data on annualized bleeding rates in children with severe hemophilia","volume":"28","author":"Ranta","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2026.06.041_bib22","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/hae.14345","article-title":"Patterns of joint damage in severe haemophilia A treated with prophylaxis","volume":"27","author":"Goren","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.06.041_bib23","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/hae.14353","article-title":"Emicizumab prophylaxis in infants with severe haemophilia A without inhibitors: illustrative real-world cases to support shared decision-making","volume":"27","author":"Mason","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.06.041_bib24","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/hae.70039","article-title":"Trends in treatment of severe haemophilia and impact on inhibitor assessment by the EUHASS registry","volume":"31","author":"Fischer","year":"2025","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.06.041_bib25","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/hae.14100","article-title":"Inhibitor development in previously untreated patients with severe haemophilia: a comparison of included patients and outcomes between a clinical study and a registry-based study","volume":"26","author":"Jonker","year":"2020","journal-title":"Haemophilia"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626004289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626004289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:15:59Z","timestamp":1785874559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783626004289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":25,"alternative-id":["S1538783626004289"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2026.06.041","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factor VIII exposure, bleeding outcomes, and inhibitor development in 80 previously untreated patients and minimally treated patients with severe hemophilia A on emicizumab prophylaxis: real-world data from the PedNet Registry","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2026.06.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}